Insights - Astria (ATXS) announced the FDA clearance of their IND application for STAR-0215 for hereditary angioedema (HAE). A Phase 1a trial of STAR-0215 in healthy volunteers … Continue Reading
Premium: Read NowInsights - A story that is developing which could impact the whole bio industry is a healthcare bill making noise in Washington. Congress and the White House are planning … Continue Reading
Premium: Read NowInsights - The biotech market saw the total EV of publicly traded companies continue to rise to start July, up by about 25% from the mid-June lows. … Continue Reading
Premium: Read NowInsights - NMTR reported data on short bowel syndrome (SBS), and it was vague, even though the company has delayed this data readout by 6 months. What … Continue Reading
Premium: Read NowInsights - F-Star (FSTX) reported yesterday that it will be acquired by invoX, a U.K.-based subsidiary of Chinese bio Sino Biopharma. Sino Bio is a global top … Continue Reading
Premium: Read NowInsights - The bio sector is seeing some life with improved fundamentals, which could be an early sign of reversal. ASCO in Chicago is wrapping up and … Continue Reading
Premium: Read NowInsights - Yesterday, Medicenna released additional data for their IL-2 program MDNA11. The 3rd cohort (n=4) used a dose of 30 µg/kg (IL-2 content of 6 µg/kg). Remember, MDNA11 is … Continue Reading
Premium: Read Now
